California vs North Carolina on USAspending: $39.5B against $6.3B

429,746 awards on $6.3B

North Carolina’s award tape is the distinctive fact. 429,746 actions on $6.3B means many small bookings relative to California’s 639,340 actions on $39.5B. North Carolina’s row count is about 67 percent of California’s on about 16 percent of the dollars. The pharmaceutical-preparation peak is consistent with many discrete manufacturing and related actions mixed into a busy statewide tape.

Population is 11,046,024 versus 39,431,263. North Carolina is about 28 percent of California’s Census count and about 16 percent of California’s $39.5B. Dollars lag population, which is why $66.77 trails $135.64. The award-count surprise does not reverse intensity.

North Carolina’s $6.3B pharmaceutical-preparation stock on 11,046,024 residents is a busy 429,746-row tape with a cool $66.77 reading; California’s $39.5B construction-led stock on 39,431,263 residents carries $135.64. FY2026 of $737.5M versus $5.3B does not reorder that ranking.

Drug manufacturing in North Carolina, buildings in California

North Carolina’s lead NAICS is pharmaceutical preparation manufacturing. California’s lead NAICS is commercial and institutional building construction. A drug-manufacturing peak on $6.3B is a different federal buying pattern than a facilities peak on $39.5B. The packet names those peaks; it does not give shares.

Use the California and North Carolina state hubs for agencies and recipients. Cite USAspending.gov. The 429,746 and 639,340 rows include many other NAICS codes. Do not treat the pharmaceutical-preparation peak as an outlay category.

FY2026: $737.5M versus $5.3B

Fiscal year 2026 obligations are $5.3B in California and $737.5M in North Carolina. North Carolina’s latest-year amount is a modest slice of $6.3B. California’s $5.3B is a modest slice of $39.5B. Recency preserves California’s lead.

Treat FY2026 as a recency slice of obligations, not Treasury cash. Do not divide $5.3B or $737.5M by 639,340 or 429,746 all-years awards. Spending per capita of $135.64 and $66.77 already uses Census denominators of 39,431,263 and 11,046,024.

Busy rows, cool dollars per resident

North Carolina’s $66.77 on 11,046,024 residents is well below California’s $135.64 on 39,431,263. The award-count surprise (429,746 vs 639,340) does not reverse intensity. It shows that a pharmaceutical-preparation-led file can be action-heavy without matching California’s $39.5B stock.

Keep every figure labeled as a USAspending.gov obligation. Outlays are a different series. Place-of-performance for pharmaceutical manufacturing can sit at a plant. The packet does not reallocate.

A pharmaceutical tape that is busy, not dollar-heavy

North Carolina’s pharmaceutical-preparation peak on $6.3B with 429,746 awards is a high-frequency manufacturing signature. California’s 639,340 awards on $39.5B remain the larger file. North Carolina’s row share is much larger than its dollar share. Spending per capita of $66.77 on 11,046,024 residents trails California’s $135.64 on 39,431,263. Frequency is North Carolina’s relative strength. Scale and intensity remain California’s.

FY2026 of $737.5M versus $5.3B restates California’s recency lead. North Carolina’s latest-year amount is a modest slice of $6.3B. Cite USAspending.gov. Outlays are a different series. Do not divide $737.5M by 429,746 all-years awards. The $66.77 and $135.64 readings already use Census denominators against the stacked stocks.

Place-of-performance for pharmaceutical manufacturing can sit at a plant. The packet does not reallocate. Use the California and North Carolina hubs for agencies and recipients. The comparison hub holds the $39.5B versus $6.3B tables. Keep 429,746 versus 639,340 labeled as all-years award counts. Commercial construction versus pharmaceutical preparations are mix tags.

North Carolina’s 429,746 awards on 11,046,024 residents under $66.77 per capita describe a busy pharmaceutical-preparation tape on $6.3B that does not match California’s $39.5B or $135.64 on 39,431,263 residents. California’s 639,340 awards remain the larger count. FY2026 of $737.5M versus $5.3B restates recency. Cite USAspending.gov. Outlays are a different series.

How to read California versus North Carolina

Read California first on stacked dollars ($39.5B vs $6.3B), spending per capita ($135.64 vs $66.77), and FY2026 ($5.3B vs $737.5M). Read North Carolina first on award volume relative to dollars: 429,746 actions on $6.3B, against 639,340 on $39.5B, with pharmaceutical preparation manufacturing as the lead industry.

The comparison hub holds the tables. Outlays are not listed.

North Carolina’s 11,046,024 residents and California’s 39,431,263 residents set the $66.77 versus $135.64 denominators on $6.3B versus $39.5B. Award counts of 429,746 versus 639,340 and FY2026 of $737.5M versus $5.3B complete the comparison. Pharmaceutical preparation manufacturing versus commercial construction remains the mix contrast. Cite USAspending.gov. Obligations, not cash paid.

Questions

Does California or North Carolina have more federal spending?

California leads stacked USAspending.gov obligations $39.5B to North Carolina’s $6.3B. California also leads spending per capita, $135.64 versus $66.77, on 39,431,263 residents against North Carolina’s 11,046,024. Award counts are 639,340 in California and 429,746 in North Carolina. FY2026 obligations are $5.3B in California and $737.5M in North Carolina.

Why does North Carolina have so many awards on $6.3B?

The packet reports 429,746 awards in North Carolina on $6.3B versus 639,340 in California on $39.5B. North Carolina’s lead industry is pharmaceutical preparation manufacturing, a mix that can generate many discrete actions. Spending per capita is $66.77 versus $135.64. These figures are USAspending.gov obligations, not outlays.

What industries lead in California and North Carolina?

California’s top industry is commercial and institutional building construction. North Carolina’s is pharmaceutical preparation manufacturing. Those labels are the largest NAICS slices on $39.5B and $6.3B. Award counts are 639,340 in California and 429,746 in North Carolina. Those peaks are mix labels on the stacked stocks, not inventories of every award.

Are California vs North Carolina figures Treasury outlays?

No. The $39.5B and $6.3B totals, and FY2026 amounts of $5.3B and $737.5M, are USAspending.gov obligations. Outlays are cash payments and can lag. Spending per capita ($135.64 vs $66.77) uses Census population where present. Award counts in the packet are all-years totals, not a single fiscal year’s actions.